Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $42.5252W HIGH $68.64
Volume
9.25 M
Value Traded
632.33 M
Short % Float
2.06%
+0.53%Week
-7.26%1 Month
-0.37%3 Month
+1.83%6 Month
-11.57%5 Year
+2,822.58%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
120.77 B
EPS (TTM)
4.54
P/E Ratio
13.01
Ent. Value
152.93 B
Total Shares
2.04 B
Float Shares
2.04 B
Insiders
0.32%
Institutions
85.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BMY Catalyst Timeline
Dated clinical, regulatory and corporate events for Bristol-Myers Squibb Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bristol-Myers Squibb Company
548Total events
34Upcoming
369Tier-1 (high impact)
2019 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutIberdomideApprovedClinical Data
Positive topline results from Phase 3 EXCALIBER-RRMM study of ZENBEXUS (iberdomide) + daratumumab + dexamethasone (ZDd)
Relapsed and Refractory Multiple Myelomasource ↗
▲Primary Endpoint MetIberdomideApprovedClinical Data
ZDd demonstrated statistically significant improvement in progression-free survival (PFS) vs DVd
Relapsed and Refractory Multiple Myelomasource ↗
▲Label ExpansionCamzyosApprovedFDA Decision
FDA approves expanded indication for CAMZYOS (mavacamten) for symptomatic oHCM in adults and pediatric patients
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲FDA ApprovalCamzyosApprovedFDA Decision
FDA approves expanded indication of CAMZYOS for oHCM in adults and pediatric patients
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
◆Oral PresentationIberdomideApprovedPresentation
First presentation of Phase 3 EXCALIBER-RRMM results for iberdomide plus daratumumab
relapsed or refractory multiple myelomasource ↗
▲Topline ReadoutIberdomideApprovedClinical Data
First presentation of Phase 3 EXCALIBER-RRMM results for ZENBEXUS (iberdomide) + daratumumab + dexamethasone
relapsed or refractory multiple myelomasource ↗
▲Primary Endpoint MetIberdomideApprovedClinical Data
Dual primary endpoint of MRD-negative CR rate met in EXCALIBER-RRMM
relapsed or refractory multiple myelomasource ↗
▲Late-BreakerIberdomideApprovedPresentation
Late-breaking oral presentation [Abstract #LBA12] at IMS 2026
relapsed or refractory multiple myelomasource ↗
▲PublicationIberdomideApprovedPresentation
Results simultaneously published in The Lancet Oncology
relapsed or refractory multiple myelomasource ↗
▲Full ResultsSotyktuApprovedClinical Data
Two-year POETYK PsA-2 OLE results presented at CCR-West
psoriatic arthritissource ↗
▲Long Term DataSotyktuApprovedClinical Data
Sotyktu two-year (Week 104) efficacy and safety data in PsA
active psoriatic arthritissource ↗
▲Oral PresentationSotyktuApprovedPresentation
Sotyktu two-year PsA data presented at CCR-West 2026
psoriatic arthritissource ↗
▲Primary Endpoint MetClinical Data
QUINTESSENTIAL met primary endpoint of ORR
quadruple-class exposed relapsed and refractory multiple myelomasource ↗
▲Secondary Endpoint DataClinical Data
Key secondary endpoint of CRR met
quadruple-class exposed relapsed and refractory multiple myelomasource ↗
▲Topline Readoutarlocabtagene autoleucelClinical Data
Positive topline results from registrational Phase 2 QUINTESSENTIAL trial of arlo-cel in quadruple-class exposed RRMM
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
▲Primary Endpoint Metarlocabtagene autoleucelClinical Data
QUINTESSENTIAL met primary endpoint of overall response rate
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
▲Secondary Endpoint Dataarlocabtagene autoleucelClinical Data
QUINTESSENTIAL met key secondary endpoints of complete response rate and ORR
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
●Safety Data Updatearlocabtagene autoleucelClinical Data
Safety profile of arlo-cel consistent with expectations
quadruple-class exposed relapsed and refractory multiple myeloma (RRMM)source ↗
▲Oral PresentationCamzyosApprovedPresentation
Late-breaker presentation of EXPLORER-LTE data at ESC Congress 2026
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲Long Term DataCamzyosApprovedClinical Data
EXPLORER-LTE data up to five years show sustained efficacy and safety
symptomatic obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲Partnership / LicenseCorporate
Chai Discovery announces collaboration with Bristol Myers Squibb for AI-driven antibody discovery
▲FDA ApprovalZENBEXUSApprovedFDA Decision
FDA granted accelerated approval to ZENBEXUS (iberdomide) for multiple myeloma
multiple myelomasource ↗
▲Primary Endpoint MetZENBEXUSApprovedClinical Data
EXCALIBER-RRMM met primary efficacy endpoint of MRD-negative complete response rate
multiple myelomasource ↗
▲FDA ApprovalZENBEXUSApprovedFDA Decision
FDA grants accelerated approval to ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
multiple myelomasource ↗
▲Primary Endpoint MetZENBEXUSApprovedClinical Data
MRD-negative CR primary endpoint met in EXCALIBER-RRMM
multiple myelomasource ↗
▲Accelerated ApprovalIberdomideApprovedFDA Decision
FDA accelerated approval of ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone
multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agentsource ↗
▲Manufacturing MilestoneCMC / Inspection
BMS selects Houston, Texas for new $2.3 billion manufacturing campus
▲Partnership / LicenseCorporate
Schrödinger announces strategic collaboration and software agreement with Bristol Myers Squibb to deploy Bunsen
▲FDA Filing AcceptedMezigdomideFiledRegulatory Filing
FDA accepts NDA for Mezigdomide in R/R multiple myeloma
Relapsed or Refractory Multiple Myelomasource ↗
▲Partnership / LicenseCeeNU®Corporate
Septa Pharmaceuticals adquiere CeeNU (Lomustina) de Bristol Myers Squibb, Canadá
tumores cerebrales, linfoma de Hodgkinsource ↗
▲Partnership / LicenseCeeNU®Corporate
Septa Pharmaceuticals acquires CeeNU (Lomustine) from Bristol Myers Squibb, Canada
brain tumors and Hodgkin's lymphomasource ↗
◆AcquisitionCeeNU®Corporate
Septa Pharmaceuticals acquires CeeNU (lomustine) from Bristol Myers Squibb Canada
brain tumors, Hodgkin lymphomasource ↗
◆Oral PresentationPresentation
Bristol Myers Squibb to participate in Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Oral Presentationizalontamab brengitecanFiledPresentation
PANKU-Breast02: izalontamab brengitecan vs physician's choice chemotherapy in TNBC
triple-negative breast cancersource ↗
◆Oral Presentationizalontamab brengitecanFiledPresentation
PANKU-Esophagus01: izalontamab brengitecan vs chemotherapy in ESCC
esophageal squamous cell carcinomasource ↗
◆Poster Presentationlisocabtagene maraleucelApprovedPresentation
Real-world patient characteristics, outcomes, and resource utilization of CAR T cell therapy across FACT and non-FACT centers in LBCL
large B-cell lymphomasource ↗
◆Oral PresentationIberdomideApprovedPresentation
Efficacy and safety of iberdomide, daratumumab, bortezomib and dexamethasone in NDMM
newly diagnosed multiple myelomasource ↗
◆Oral PresentationPumitamigPresentation
Phase 2 data from ROSETTA Lung-02: pumitamig + chemotherapy in 1L NSCLC
non-small cell lung cancersource ↗
▲Late-BreakerMezigdomideFiledPresentation
Late-breaking oral presentation of SUCCESSOR-2 results at ASCO 2026
relapsed or refractory multiple myelomasource ↗
◆Oral PresentationMezigdomideFiledPresentation
Mezigdomide, carfilzomib, and dexamethasone vs carfilzomib and dexamethasone in RRMM: results from Phase 3 SUCCESSOR-2 trial (LBA)
relapsed or refractory multiple myelomasource ↗
▲Primary Endpoint MetMezigdomideFiledClinical Data
SUCCESSOR-2 met primary endpoint of PFS with HR 0.48
relapsed or refractory multiple myelomasource ↗
▲Full ResultsMezigdomideFiledClinical Data
Full results of SUCCESSOR-2 presented at ASCO 2026
relapsed or refractory multiple myelomasource ↗
◆Oral PresentationGolcadomidePresentation
Golcadomide + pola-RCHP in newly diagnosed aggressive B-cell lymphoma: safety and 12-month efficacy
aggressive B-cell lymphomasource ↗
▲Partnership / LicenseCorporate
Foundation Medicine expands collaboration with Bristol Myers Squibb to develop FoundationOne CDx as companion diagnostic for MTAP deletion
multiple indicationssource ↗
▲Partnership / LicenseCorporate
Oxford BioTherapeutics enters strategic collaboration with Bristol Myers Squibb to discover and develop T-cell engagers for solid tumours
solid tumourssource ↗
◆PDUFA DateNivolumabApprovedRegulatory Filing
PDUFA goal date for Opdivo + AVD sBLA
classical Hodgkin lymphomasource ↗
▲Topline ReadoutCamzyosApprovedClinical Data
Positive topline results from Phase 3 SCOUT-HCM trial of Camzyos in adolescents with oHCM
symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescentssource ↗
▲Primary Endpoint MetCamzyosApprovedClinical Data
Primary endpoint met: statistically significant reduction in Valsalva LVOT gradient at Week 28
symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescentssource ↗
Past FDA Catalysts and PDUFA Decisions
How BMY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Camzyos (mavacamten) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A83 / 100
Pipeline Score
$34.9B
Pipeline Value
$210.5B
Commercial Value
Undervalued
Valuation Signal
140
Drugs Scored
1.0x
rNPV / MCap
Top 2%
Large Pharma(rank 14 of 660)
Percentile Rank
Bristol-Myers Squibb Company earns an A-grade pipeline score (83/100), with $34.9B risk-adjusted pipeline value, led by Pneumococcal polysaccharide vaccine in Multiple Sclerosis (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $49.2B x 4.3 = $210.5B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Eliquis | $15.8B | $13.4B | +17.7% |
| Opdivo | $9.9B | $9.7B | +2% |
| Orencia | $3.8B | $3.7B | +4.2% |
| Yervoy | $3.0B | $2.7B | +11.3% |
| Reblozyl | $2.6B | $2.0B | +26.1% |
| Pomalyst/Imnovid | $2.1B | $3.1B | -32.5% |
| Revlimid | $2.0B | $4.5B | -56.9% |
| Breyanzi | $1.6B | $1.1B | +50.5% |
| Camzyos | $1.4B | $798M | +72.7% |
| Opdualag | $1.3B | $1.0B | +26.2% |
| Opdivo Qvantig | $624M | - | - |
| Zeposia | $607M | $562M | +8% |
Top 12 of 17 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pneumococcal polysaccharide vaccine VaccineCompletedNCT05028634 | Multiple Sclerosis | Phase 3 | COMPLETED | 63 | Nov 15, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every BMY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Camzyos | symptomatic obstructive hypertrophic cardiomyopathy | 2026-08-29 | up to five yearsRead More | Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gallman CariOfficer (EVP, General Counsel) | Option | 4,559 18,208 held | $0.00 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BMY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1 % (-9.1 %) | 53.30 M | 925.00 K |
BMY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-27 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BMY ranks across every disease it competes in
Competitive Position is a premium feature
See how BMY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBMY News
BMY▼ -0.7%today
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Bristol Myers Squibb has announced that ZENBEXUSTM (iberdomide), in combination with Daratumumab and Dexamethasone, has demonstrated superior progression-free survival compared to standard care in patients with relapsed and refractory multiple myeloma. This finding comes from a Phase 3 clinical trial, highlighting the potential of this combination therapy to improve treatment outcomes for patients.
Read more →BMYDriving Community Health: Bristol Myers Squibb, Emirates Thalassemia Society and Dubai Science Park Host the 6th 'Help Save a Life' Blood Donation Drive
Bristol Myers Squibb, in collaboration with the Emirates Thalassemia Society and Dubai Science Park, hosted the sixth 'Help Save a Life' blood donation drive in Dubai. This initiative aims to support patients with chronic blood disorders by mobilizing community members to donate blood. The event highlights the importance of reliable blood supplies for patients' treatment and reinforces the commitment to patient care in the UAE.
Read more →BMYBristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol Myers Squibb has expanded its Champions in Care initiative, now in its second year, to honor healthcare professionals and support medically underserved communities. The campaign introduces a $1 million grant program for nonprofit organizations, allowing healthcare professionals to nominate groups that address community healthcare gaps. Nominations are open until November 30, 2026.
Read more →BMYU.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
The U.S. FDA has approved an expanded indication for Bristol Myers Squibb's CAMZYOS (mavacamten), allowing its use in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in both adults and pediatric patients. This approval reflects the drug's efficacy and the company's commitment to addressing this serious condition. The expanded use is expected to enhance treatment options for patients suffering from oHCM.
Read more →BMYBristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb has announced the first presentation of results for ZENBEXUS™ (iberdomide) in combination with Daratumumab from the Phase 3 EXCALIBER-RRMM trial. This trial focuses on patients with relapsed or refractory multiple myeloma, showcasing the potential of this combination therapy. The announcement marks a significant step in the ongoing development of innovative treatments for this patient population.
Read more →BMYNew Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP
Bristol Myers Squibb (BMS) has joined the Rare Access Action Project (RAAP) to enhance efforts in addressing access challenges for rare disease patients. BMS's participation is expected to bring valuable insights and strengthen the coalition's mission to improve patient access to innovative treatments. The collaboration aims to foster solutions that benefit patients facing serious diseases.
Read more →BMYBristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Bristol Myers Squibb will report its financial results for the third quarter of 2026 on October 29, 2026. The announcement will be followed by a conference call at 8:00 a.m. ET, where company executives will discuss the results. Investors and the public can access the live audio webcast and related materials on the company's Investor Relations website.
Read more →BMYBristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Bristol Myers Squibb has presented data on Sotyktu (deucravacitinib) showing its durable efficacy and consistent safety in adults with psoriatic arthritis over a two-year period. The findings were shared at the CCR West 2026 conference, highlighting the drug's positive impact on patient outcomes. This data reinforces Sotyktu's role in treating this condition.
Read more →BMYBristol Myers Squibb Announces Dividend
Bristol Myers Squibb has declared a quarterly dividend of $0.63 per share, payable on November 2, 2026. Shareholders of record as of October 2, 2026, will receive this dividend. The announcement underscores the company's commitment to returning value to its investors while continuing its mission in innovative medicine.
Read more →BMYBristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Bristol Myers Squibb has announced positive topline results from its registrational Phase 2 QUINTESSENTIAL trial for Arlocabtagene Autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy. This development marks a significant step forward in the treatment landscape for patients. The results may pave the way for future regulatory submissions.
Read more →BMYBristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Bristol Myers Squibb presented new data at the ESC Congress 2026, showcasing the long-term efficacy and safety of Camzyos (mavacamten) in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The findings, which span up to five years, reinforce the drug's positive profile in managing this condition. This presentation underscores the importance of ongoing research in cardiovascular therapies.
Read more →BMYChai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
Chai Discovery has announced a collaboration with Bristol Myers Squibb to enhance antibody discovery through artificial intelligence. This partnership aims to leverage AI technology to improve the efficiency and effectiveness of the antibody development process. The collaboration signifies a commitment to innovation in the biopharma sector.
Read more →BMYFESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb
The 32nd Annual One Mind Music Festival is set for September 19, 2026, at the Staglin Family Vineyard in Napa Valley. Sponsored by Bank of America and Bristol Myers Squibb, the festival will feature The Fray, celebrating the 20th anniversary of their song 'How to Save a Life'. The event combines music, science, and culinary experiences.
Read more →BMYHematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix's MM MRD assay was instrumental in the FDA's accelerated approval of ZENBEXUS (iberdomide), marking it as the first CELMoD therapy for multiple myeloma. The assay demonstrated a significant improvement in MRD-negative complete response rates in clinical trials. This milestone underscores Hematogenix's expertise in oncology trials and the growing importance of MRD negativity in treatment success.
Read more →BMYU.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
The U.S. FDA has granted accelerated approval for Bristol Myers Squibb's ZENBEXUS, the company's first CELMoD therapy. This therapy is approved for use in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) in patients with multiple myeloma, particularly as early as the first relapse. This marks a significant advancement in treatment options for this patient population.
Read more →BMYBristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
Bristol Myers Squibb has announced a significant investment of $2.3 billion to establish a new manufacturing campus in Houston, Texas. This initiative aims to bolster their production capabilities and support local job growth. The investment reflects the company's commitment to enhancing its manufacturing footprint in the U.S.
Read more →BMYSchrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
Schrödinger, Inc. has entered a strategic collaboration with Bristol Myers Squibb (BMS) to implement Bunsen, an AI co-scientist, in its research efforts. This partnership aims to enhance drug discovery processes through advanced artificial intelligence. The collaboration highlights the growing importance of AI in biopharma research.
Read more →BMYBristol Myers Squibb Reports Second Quarter Financial Results for 2026
Bristol Myers Squibb reported a strong performance in Q2 2026, with revenues rising 6% to $13.0 billion, driven by a 15% increase in its Growth Portfolio. The company raised its full-year revenue guidance to approximately $49.0 billion to $50.0 billion. However, the Legacy Portfolio saw a 4% decline in revenues due to generic competition. Overall, the results reflect a solid pipeline and operational execution.
Read more →BMYBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
Bristol Myers Squibb has announced plans to establish a powerful AI factory in collaboration with NVIDIA. This initiative is expected to significantly enhance capabilities in drug discovery and development within the life sciences sector. The partnership highlights the growing importance of artificial intelligence in advancing healthcare solutions.
Read more →About Bristol-Myers Squibb Company
HeadquartersROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
BIOPHARMAWATCH ELITE PLUS
Trade the next BMY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime